The Korean Influenza National Immunization Program: History and Present Status

The Korean influenza national immunization program was first established as an interim program in 1997, administering the influenza vaccine to low-income elderly adults. In 2005, the program assumed its present form of providing free influenza vaccination to adults aged ≥65 years. After turning over...

Full description

Saved in:
Bibliographic Details
Published inInfection & chemotherapy Vol. 49; no. 4; pp. 247 - 254
Main Authors Yun, Jae-Won, Noh, Ji Yun, Song, Joon Young, Chun, Chaemin, Kim, Yunju, Cheong, Hee Jin
Format Journal Article
LanguageEnglish
Published Korea (South) The Korean Society of Infectious Diseases and Korean Society for Chemotherapy 01.12.2017
대한감염학회
Subjects
Online AccessGet full text
ISSN2093-2340
2092-6448
DOI10.3947/ic.2017.49.4.247

Cover

Loading…
More Information
Summary:The Korean influenza national immunization program was first established as an interim program in 1997, administering the influenza vaccine to low-income elderly adults. In 2005, the program assumed its present form of providing free influenza vaccination to adults aged ≥65 years. After turning over the influenza vaccination for elderly adults to the private sectors in 2015, the influenza vaccination coverage rate among this population increased to >80%. In addition, after the 2009 H1N1 influenza epidemic crisis, the vaccine was domestically produced. By reaching a 75% vaccination coverage rate in the target groups, it was possible to put an end to the influenza pandemic and fix the shortcomings of the system that existed at that time. The influenza vaccination program, provided free of cost, was extended to include infants aged <12 months in 2016 and ≤59 months in 2017 in order to reduce the influenza burden in these populations. However, the vaccine effectiveness remains low despite the high vaccination rates in elderly adults. Therefore, several areas, such as the adoption of quadrivalent influenza vaccine, adjuvanted influenza vaccine, and high-dose influenza vaccine and the expansion of vaccination target groups, still need to be addressed.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:2093-2340
2092-6448
DOI:10.3947/ic.2017.49.4.247